Seismic Therapeutic Inc.'s S-1117 was designed as a pan-IgG protease fused to an effector function silent human IgG1 Fc domain. The candidate, being developed for the treatment of autoantibody-mediated diseases, was engineered for chronic subcutaneous administration using a proprietary machine learning-enabled platform, with the aim of reducing immunogenicity while maintaining potency.